MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

9864	Companies
198258	Keywords
129309	Articles
105439	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 08/19/2025 at 14:30, 5 months 25 days ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
MIRA Pharmaceuticals, Inc. announces successful completion of Phase 1 Single Ascending Dose trial for oral Ketamir-2, preparing for U.S. Phase 2a trial in Q4 2025

Clinical Trial Phase 1 MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 08/12/2025 at 14:35, 6 months 1 day ago

MIRA Pharmaceuticals développe le kétamir-2 pour le traitement de la douleur neuropathique

Essais Cliniques Croissance Du Marché Médicaments Ketamir-2 Douleur Neuropathique
BRIEF

published on 08/12/2025 at 14:35, 6 months 1 day ago

MIRA Pharmaceuticals Advances Ketamir-2 for Neuropathic Pain Treatment

Pharmaceuticals Clinical Trials Market Growth Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 08/12/2025 at 14:30, 6 months 1 day ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
MIRA Pharmaceuticals announces the acceptance of a manuscript in Frontiers in Pharmacology detailing Ketamir-2's efficacy in neuropathic pain, supporting Phase 2a trials by 2025

Clinical Trials MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pharmacology
BRIEF

published on 07/30/2025 at 13:35, 6 months 14 days ago

Le kétamir-2 topique de MIRA Pharmaceuticals est comparable à la morphine injectée dans une étude sur la douleur

Soulagement De La Douleur Étude Préclinique Kétamir-2 Topique Comparaison De La Morphine Traitement Localisé
BRIEF

published on 07/30/2025 at 13:35, 6 months 14 days ago

MIRA Pharmaceuticals' Topical Ketamir-2 Matches Injected Morphine in Pain Study

Preclinical Study Pain Relief Topical Ketamir-2 Morphine Comparison Localized Treatment
PRESS RELEASE

published on 07/30/2025 at 13:30, 6 months 14 days ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
MIRA Pharmaceuticals announces new preclinical data showing topical Ketamir-2 provides effective pain relief comparable to injected morphine in animal models. The treatment has potential for both centralized and localized pain pathways

Preclinical Data MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Topical Pain Relief
BRIEF

published on 07/29/2025 at 13:35, 6 months 15 days ago

MIRA Pharmaceuticals reçoit le feu vert de la FDA pour les essais du kétamir-2

Autorisation De La FDA Expansion Stratégique Ketamir-2 Douleur Neuropathique Essai De Phase 1
BRIEF

published on 07/29/2025 at 13:35, 6 months 15 days ago

MIRA Pharmaceuticals Receives FDA Green Light for Ketamir-2 Trials

FDA Clearance Phase 1 Trial Strategic Expansion Ketamir-2 Neuropathic Pain
PRESS RELEASE

published on 07/29/2025 at 13:30, 6 months 15 days ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
MIRA Pharmaceuticals advances non-opioid oral drug Ketamir-2 for neuropathic pain, clears FDA IND for Phase 2a, demonstrates potent effects in preclinical studies

FDA Preclinical Studies MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain

Accesswire

Published on 02/14/2026 at 01:00, 11 hours 38 minutes ago

Orogen Royalties Announces Annual Equity Compensation Grant
Published on 02/13/2026 at 22:30, 14 hours 8 minutes ago

Norse Gold Corp. Announces New Director
Published on 02/13/2026 at 22:15, 14 hours 23 minutes ago

Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 18 hours 53 minutes ago

Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 22 hours 3 minutes ago

Datametrex Received $500,000 Purchase Order For Data Centre Solutions

View all ACCESSWIRE

EQS Group

Published on 02/14/2026 at 06:05, 6 hours 33 minutes ago

The 139th Canton Fair Promotion Conferences to Be Held in Germany and Morocco, Highlighting Targeted Industry Opportunities
Published on 02/13/2026 at 19:20, 17 hours 18 minutes ago

Retail offering successfully completed and update on Euronext Growth Oslo listing
Published on 02/13/2026 at 19:01, 17 hours 37 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/13/2026 at 18:20, 18 hours 18 minutes ago

GLOBAL TECHNOLOGY LEADERS LAUNCH TRUSTED TECH ALLIANCE
Published on 02/13/2026 at 18:07, 18 hours 30 minutes ago

EQS-Adhoc: Delticom AG: Based on preliminary, unaudited figures for the FY 2025, full-year revenues are below the forecast, while operating EBITDA is expected to be at the upper end of the forecasted range

Les Echos

Published on 02/14/2026 at 07:00, 5 hours 38 minutes ago

Groupe DLSI - Chiffre d'affaires 2025
Published on 02/13/2026 at 18:05, 18 hours 33 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 18 hours 33 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 18 hours 48 minutes ago

Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 18 hours 48 minutes ago

Nombre total d'actions et droits de vote - janvier 2026

View all LES ECHOS COMFI WIRE